Opus forms epileptic drug monitoring deal:
This article was originally published in Clinica
Executive Summary
Opus Diagnostics has entered into an exclusive licence agreement with Dainippon Pharmaceuticals, whereby Opus will develop a diagnostic test to monitor blood levels of the anti-epileptic drug, Zonisamide. The test is expected to monitor levels of the drug in selected patients in order to help physicians optimise dosage and patient outcomes. Zonisamide, developed by Osaka, Japan-based Dainippon, is licensed in the US and Europe to Elan Pharmaceuticals. Opus, a wholly owned subsidiary of Fort Lee, New Jersey-based Caprius, says it is investigating other opportunities of co-operation with Dainippon in the diagnostics field.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.